For more than four years, Novartis has foot the bill for a partner’s preclinical development of molecules with the potential to target a pathway implicated in inflammatory disorders. Now the pharmaceutical giant has seen enough progress to plunk down $90 million to buy the company, IFM Due, and continue its inflammation drug research.
The acquisition announced Wednesday is the culmination of a 2019 agreement that Novartis reached with IFM Due’s parent company, IFM Therapeutics. In exchange for fully funding IFM Due’s R&D, the deal gave Novartis an option to acquire all of that biotech’s stock.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
IFM Due’s research focuses on cGAS, a protein that regulates STING, a pathway in the innate immune system that senses signals of cellular danger. Picking up these signals triggers an inflammatory response. Inappropriate activation of the STING pathway leads to excessive signaling that drives inflammation. IFM Therapeutics says dysregulation of this pathway could be the basis of several inflammatory disorders. Specific diseases covered by IFM Due’s research remain undisclosed. But Novartis now has full rights to IFM Due’s portfolio of small molecules that could potentially treat conditions driven by excessive STING pathway activity.
The Novartis acquisition marks the third exit event for IFM Therapeutics. The Boston company houses its research in subsidiaries, a corporate structure that enables each business unit to strike up partnerships with big pharmaceutical companies that can finance the research and potentially acquire it. The first such deal was Bristol Myers Squibb’s 2017 acquisition of IFM Therapeutics’ cancer immunotherapy research for $300 million up front. In 2019, Novartis paid $310 million up front to acquire IFM Tre, a clinical-stage IFM Therapeutics subsidiary whose lead program was a treatment for the fatty liver disease now known as MASH.
Like the prior two IFM Therapeutics deals, the latest acquisition could pay out more depending on the progress of the research. IFM Due milestones could add another $745 million to Novartis’s tab.
“The acquisition of IFM Due represents the culmination of a highly productive, four-year preclinical collaboration between Novartis and IFM to develop novel small-molecule STING inhibitors with the potential to treat a spectrum of inflammatory diseases,” Richard Siegal, global head of immunology research at Novartis, said in a prepared statement. “We are excited to advance IFM Due’s STING program and leverage our deep expertise in inflammation science to bring forward transformative medicines that address major unmet patient needs.”
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Novartis’s IFM Due acquisition comes as a potential rival makes progress with its own research drugging the cGAS-STING pathway. At the start of this year, Ventus Therapeutics began a Phase 1 trial for VENT-03, a molecule the company claims is the first cGAS inhibitor to enter clinical development.
In an interview during the J.P. Morgan Health Care Conference in San Francisco in January, Ventus CEO Marcelo Bigal said previous efforts to drug cGAS have fallen short because even though drug hunters could hit the target, their molecules failed to show sufficient potency to make them viable medicines. Bigal said the cell is a dynamic environment in which protein shapes change with the movement of fluid. Ventus’s ReSOLVE technology analyzes proteins in this watery environment to find the pockets where a molecule can bind to its target.
“If the proof is in the pudding, I think what ReSOLVE has is the pudding,” Bigal said.
Ventus’s Phase 1 trial of VENT-03 is testing various doses of the drug candidate in healthy volunteers. Preliminary data are expected in the second half of this year.
Photo: Adrian Moser/Bloomberg, via Getty Images
